Bcl-xS/L Antibody (2H12): sc-23958

Bcl-xS/L Antibody (2H12) is a mouse monoclonal IgG2a kappa light chain antibody that detects Bcl-xS/L protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry. Anti-Bcl-xS/L antibody (2H12) is available as the non-conjugated form. Bcl-xS/L protein plays a crucial role in regulating apoptosis, a process of programmed cell death essential for maintaining cellular homeostasis and development. Bcl-xS is a shorter isoform of Bcl-xL, which inhibits apoptosis, while Bcl-xS acts as a dominant negative regulator, promoting cell death by antagonizing the protective effects of Bcl-xL and Bcl-2. This balance between pro-apoptotic and anti-apoptotic proteins is vital for normal cellular function, and dysregulation can lead to various diseases, including cancer. Bcl-xS interactions with other members of the Bcl-2 family, such as Bax and Bad, further underscore Bcl-xS importance in the apoptotic pathway, as these interactions can determine cell fate in response to stress signals. Using Bcl-xS/L (2H12) antibody in research can provide valuable insights into apoptosis mechanisms and Bcl-xS/L role in various biological processes and disease states.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Bcl-xS/L Antibody (2H12) References:

1. Sequential cleavage of poly(ADP-ribose)polymerase and appearance of a small Bax-immunoreactive protein are blocked by Bcl-X(L) and caspase inhibitors during staurosporine-induced dopaminergic neuronal apoptosis.  |  Kim, JE., et al. 1999. J Neurochem. 72: 2456-63. PMID: 10349855
2. Induction of Bcl-x(L) expression by human T-cell leukemia virus type 1 Tax through NF-kappaB in apoptosis-resistant T-cell transfectants with Tax.  |  Tsukahara, T., et al. 1999. J Virol. 73: 7981-7. PMID: 10482545
3. The anti-apoptotic genes Bcl-X(L) and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34+ cells.  |  Konopleva, M., et al. 2002. Br J Haematol. 118: 521-34. PMID: 12139741
4. Atypical antipsychotics attenuate neurotoxicity of beta-amyloid(25-35) by modulating Bax and Bcl-X(l/s) expression and localization.  |  Wei, Z., et al. 2003. J Neurosci Res. 74: 942-7. PMID: 14648600
5. BCL2L1 (BCL-X) promotes survival of adult and developing retinal ganglion cells.  |  Harder, JM., et al. 2012. Mol Cell Neurosci. 51: 53-9. PMID: 22836101
6. Molecular mechanism of the miR-7/BCL2L1/P53 signaling axis regulating the progression of hepatocellular carcinoma.  |  Zhang, N., et al. 2023. Ann Transl Med. 11: 12. PMID: 36760243
7. BCL2L1 inhibitor A-1331852 inhibits MCL1 transcription and triggers apoptosis in acute myeloid leukemia cells.  |  Chiou, JT., et al. 2023. Biochem Pharmacol. 215: 115738. PMID: 37562509
8. ATP1A1/BCL2L1 predicts the response of myelomonocytic and monocytic acute myeloid leukemia to cardiac glycosides.  |  Cerella, C., et al. 2024. Leukemia. 38: 67-81. PMID: 37904054
9. Bcl2l1 Deficiency in Osteoblasts Reduces the Trabecular Bone Due to Enhanced Osteoclastogenesis Likely through Osteoblast Apoptosis.  |  Moriishi, T., et al. 2023. Int J Mol Sci. 24: PMID: 38139148
10. Genome-wide CRISPR screen reveals the synthetic lethality between BCL2L1 inhibition and radiotherapy.  |  Yin, L., et al. 2024. Life Sci Alliance. 7: PMID: 38316463

The preferred Bcl-x_L antibody is Bcl-x_L Antibody (H-5): sc-8392.